Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.

ABSTRACT: Bosutinib has been evaluated for treatment of chronic-phase chronic myeloid leukemia (CP-CML) in several clinical studies, including in Japan. This open-label, single-arm, phase 2 study evaluated the efficacy and safety of bosutinib at a starting dose of 400 mg once daily in Japanese patients (n = 60) with newly diagnosed CP-CML. The minimum follow-up period was 3 years and median duration of treatment was 35.9 months. At study completion, 60% of patients were still on treatment. Cumulative rates of major molecular response (MMR), molecular response⁴ (MR⁴), and MR^4.5 at any time were 70.0%, 53.3%, and 48.3%, respectively. No patient who achieved MMR or MR⁴ had a confirmed loss of response. No patient experienced on-treatment transformation to acc

SUBMITTER: Ono T 

PROVIDER: S-EPMC9668794 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature